ClinicalTrials.gg
RecruitingNCT07334457ECMO-POPUpdated Jan 12, 2026

Study of Platelet Population Changes Under Circulatory Support With ECMO

An observational study in Cardiac Failure and Respiratory Failure, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.

Planned enrollment
137th of 161
75 · median 321
Started
2025
with 28 others
Observational
161 of 448
28 open now
Primary completion
2027-03
later than 43 of 115 live
Registered
418th of 448
by date

Among the 448 studies in Heart Failure with a site in France, this one is the 137th largest by planned enrollment of the 161 observational ones that give a count, is one of 29 that started in 2025, is one of 161 observational ones, reaches primary completion later than 43 of the 115 other live ones, and was the 418th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Heart Failure with a site in France, or all of them as a file.
02

Study summary

Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.

03

Conditions studied

  • Cardiac Failure
  • Respiratory Failure

Keywords

  • Cardiac Failure
  • Respiratory Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

- Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital and implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital.
  • Implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.

Exclusion criteria

Exclusion Criteria:

  • Subject who has expressed their opposition to participating in the study.
  • Subject under legal protection.
  • Subject under guardianship or curatorship.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
75 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic)

    Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) on Days 1, 3, and 7 after the initiation of ECMO treatment.

    Time frame: Days 1, 3, and 7 after the initiation of ECMO treatment.

07

Study locations

1 of 1 sites recruiting
  • Service d'anesthésie-réanimation - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • Charles TACQUARD, MD, PhD · Contactcharlesambroise.tacquard@chru-strasbourg.fr · 33.3.69.55.16.08
    • Charles TACQUARD, MD, PhD · Principal investigator
    • Marie MULLER, MD · Sub investigator
    • Thomas RESCHWEIN, MD · Sub investigator
    • Walid OULEHRI, MD · Sub investigator
    • Laurent SATTLER, MD · Sub investigator
    • Béatrice HECHLER, Statistician · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 12, 2026
StartActual
Mar 11, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 11, 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07334457
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Mar 11, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 11, 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

Charles TACQUARD, MD, PhD
Contact
charlesambroise.tacquard@chru-strasbourg.fr
33.3.69.55.16.08

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion